Weir M R
Clinical Research Unit, University of Maryland School of Medicine, Baltimore 21201, USA.
Am J Nephrol. 1996;16(3):237-45. doi: 10.1159/000169003.
Increased urinary albumin excretion is a good predictor of future progression of renal disease in patients with both insulin-dependent and non-insulin-dependent diabetes mellitus. In addition, it is an independent predictor of cardiovascular morbidity and mortality in patients with essential hypertension. Whether urinary albumin excretion represents a prognostic indicator for progressive renal dysfunction in patients with normal blood pressure, or essential hypertension and normal renal function, remains to be determined. In patients with diabetic renal disease, urinary albumin excretion is a good predictor for the future development of renal injury, and an effort has thus been made to study the success of antiproteinuric therapies in delaying progression of renal injury. Some antihypertensive agents have demonstrated abilities to reduce urinary albumin excretion either with or without a reduction in systemic arterial pressure. Whether the abilities of these drugs to protect renal function is related to their antihypertensive effects or antiproteinuric effects, or both, is unknown. This review will explore the influence of different antihypertensive agents on urinary albumin excretion in patients with and without essential hypertension, as well as in patients with nondiabetic and diabetic renal disease.
尿白蛋白排泄增加是胰岛素依赖型和非胰岛素依赖型糖尿病患者未来肾病进展的良好预测指标。此外,它是原发性高血压患者心血管发病和死亡的独立预测指标。尿白蛋白排泄是否代表血压正常、原发性高血压且肾功能正常患者进行性肾功能不全的预后指标,仍有待确定。在糖尿病肾病患者中,尿白蛋白排泄是肾损伤未来发展的良好预测指标,因此人们努力研究抗蛋白尿疗法在延缓肾损伤进展方面的成效。一些抗高血压药物已显示出无论是否降低体循环动脉压都有降低尿白蛋白排泄的能力。这些药物保护肾功能的能力是与其降压作用还是抗蛋白尿作用相关,抑或是两者都相关,尚不清楚。本综述将探讨不同抗高血压药物对有或无原发性高血压患者以及非糖尿病和糖尿病肾病患者尿白蛋白排泄的影响。